Disease · MONDO_0019088

post-transplant lymphoproliferative disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. post-transplant lymphoproliferative disease. Diseases, record MONDO_0019088. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019088

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: post-transplant lymphoproliferative disease; Open Targets
Open Targets ID: MONDO_0019088; Open Targets
Other names: PTLD, post-transplant lymphoproliferative disorder; Open Targets
NCI Thesaurus: C4727; NCI Thesaurus
Orphanet: ORPHA:70568; Orphanet
Highest stage of its drugs: Phase 3, for 1 of its 23 drugs, from ClinicalTrials.gov and TTD; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TABELECLEUCEL	CHEMBL3990008	Cell	Phase 3	ClinicalTrials.gov and TTD	4	2	2	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	14	14	14	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
BENDAMUSTINE	CHEMBL487253	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BORTEZOMIB	CHEMBL325041	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BALTALEUCEL-T	CHEMBL3990003	Cell	Phase 2	ClinicalTrials.gov and TTD	2	1	1	Drugs and targets
ACALABRUTINIB	CHEMBL3707348	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets68

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	3	B-lymphocyte antigen CD20 binding agent	Phase 2	https://conductscience.org/library/genes/931	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 68

See all 68 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT05011058	An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas	Phase 2	102	2025-07-28	Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder	NANATINOSTAT, VALGANCICLOVIR	Open Targets' reading of its record	ClinicalTrials.gov
NCT00066469	Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation	Phase 2	55	2014-01-17	Lymphoproliferative Disorder	CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE, PREDNISONE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02900976	Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder	Phase 2	18	2022-06-03	EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder	RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01058239	Bortezomib Plus Rituximab for EBV+ PTLD	Phase 2	7	2018-02-15	Post-transplant Lymphoproliferative Disease, Solid Organ Transplant, Stem Cell Transplant (Bone Marrow Transplant), Epstein Barr Virus Infections	BORTEZOMIB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT04337827	Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder	Phase 2	6	2024-04-10	Post-transplant Lymphoproliferative Disorder	ACALABRUTINIB, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00869323	Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders	Phase 2	3	2017-04-05	Lymphoproliferative Disorder	BORTEZOMIB, RITUXIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02763254	Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas	Phase 2	1	2019-03-12	Hodgkin Lymphoma, Lymphoma, Large B-Cell, Diffuse, Post-transplant Lymphoproliferative Disorder	BALTALEUCEL-T	Its record names the disease	ClinicalTrials.gov
NCT01656343	Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients		775		Kidney Transplantation, Transplantation, Kidney	BELATACEPT	Its record names the disease	ClinicalTrials.gov
NCT04554914	A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases	Phase 2	190		Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma	TABELECLEUCEL	Its record names the disease	ClinicalTrials.gov
NCT02000934	A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies	Phase 1	143		Advanced Solid Tumor and Lymphoma Malignancies	MIVAVOTINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
35974101	RESULT	1	PubMed
22883417	RESULT	1	PubMed
39792912	DERIVED	1	PubMed
38309282	DERIVED	1	PubMed
38163318	DERIVED	1	PubMed
37530631	DERIVED	1	PubMed
36702329	DERIVED	1	PubMed
32327472	DERIVED	1	PubMed
27992268	DERIVED	1	PubMed
22173060	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019088

GET https://conductscience.org/api/diseases/v1/MONDO_0019088/drugs?page=2

API reference For AI assistants